All In Biotech

Drug Trial Radar · NCT01784536

Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail

Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 2013

Primary completion

Mar 2013

Study completion Mar 2013

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 6, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.

Conditions

  • Healthy

Interventions

  • Single-Dose IV Oritavancin DiphosphateDrug

    Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the phenotyping measures of each probe drug in the absence and presence of oritavancinTime frame: Day 1 through Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Spaulding Clinical

    West Bend, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.